Notice NOT-OH-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-033 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-039 from the NIH Guide for Grants and Contracts

Notice NOT-GM-22-017 from the NIH Guide for Grants and Contracts

Notice NOT-GM-22-026 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-058 from the NIH Guide for Grants and Contracts. NCATS is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS. Please see Determination that a Public Health Emergency Exists Nationwide as the Result of the Opioid Crisis as renewed in Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of the Opioid Crisis.This Funding Opportunity Announcement (FOA) invites applications from early and mid-career investigators (i.e. postdoctoral fellow/associates associate professor) who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of therapeutic drug, biologic, or device development.

Notice NOT-HL-23-003 from the NIH Guide for Grants and Contracts

Notice NOT-DA-23-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-099 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.

Funding Opportunity PAR-22-084 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Funding Opportunity PAR-22-083 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Funding Opportunity RFA-ES-22-002 from the NIH Guide for Grants and Contracts. The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program is intended to provide support for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award to support the majority of their independent environmental health sciences research program.

Funding Opportunity RFA-HD-22-024 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support interdisciplinary community-engaged research designed to reduce or eliminate infections and sepsis as causes of pregnancy-related or associated morbidity and mortality (PRAMM) in regions of the United States with high rates of maternal mortality. This FOA is to support research primarily focused on PRAMM health disparities in areas with highest maternal morbidity and mortality.

Funding Opportunity PAR-22-102 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol associated organ damage (AAOD). As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. Projects responsive to this announcement could be undertaken at any point along the drug development continuum, from late discovery (i.e., lead optimization/early safety) up to early-stage clinical trials. For small molecules, the earliest stage of eligibility for this Award is already having small-molecule compounds with proof of desired pharmacological activity. For biologics, the profiling of promising product candidates in animal models of AUD or AAOD will be allowed as the earliest entry point. The ultimate purpose and goal of this FOA is to advance molecules closer to U.S. Food and Drug Administration (FDA) approval. Milestones will be commensurate with the project proposed and the purpose of this FOA. This FOA supports early-phase clinical trials, although these are not required. Women-owned and Small Disadvantaged small business are encouraged to apply.

Funding Opportunity PAR-22-103 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol associated organ damage (AAOD). As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. Projects responsive to this announcement could be undertaken at any point along the drug development continuum, from late discovery (i.e., lead optimization/early safety) up to early-stage clinical trials. For small molecules, the earliest stage of eligibility for this Award is already having small-molecule compounds with proof of desired pharmacological activity. For biologics, the profiling of promising product candidates in animal models of AUD or AAOD will be allowed as the earliest entry point. The ultimate purpose and goal of this FOA is to advance molecules closer to U.S. Food and Drug Administration (FDA) approval. Milestones will be commensurate with the project proposed and the purpose of this FOA. This FOA supports early-phase clinical trials, although these are not required. Women-owned and Small Disadvantaged small business are encouraged to apply.

Competitive Salary: Rothamsted Research: KnetMiner (https://knetminer.com) is an innovative gene discovery and analytics platform using Knowledge Graphs... Harpenden

EUR 3.945,90 (following the recommendations of FWF): CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: We are seeking an enthusiastic and energetic candidate for a Data Scientist in Metabolomics position to...... Vienna (AT)

Competitive Salary: EMBL: The Open Targets (OT) project aims to systematically identify and prioritise drug targets by combining genetic, clinical and functional genomics data. Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: Are you creative, curious, and ambitious and like to tackle challenging biological data analysis problems? We have an exciting opportunity for a bio Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: ELIXIR is seeking an experienced bioinformatician who can combine technical understanding of current trends in bioinformatics software (development an Hinxton, Cambridgeshire, England